業績集‎ > ‎

2010


1. Abe Y, Sakairi T, Kajiyama H, Shrivastav S, Beeson C, Kopp JB. Bioenergetic characterization of mouse podocytes. Am J Physiol Cell Physiol.299:464-476, 2010.

2. Akiyasu T, Paudyal B, Paudyal P, Kumiko M, Kazue U, Takuji N, Takashi K, Yoshihisa N, Minoru K. A case report of acute renal failure associated with beepollen contained in nutritional supplements. Ther Apher Dial.14:93-97, 2010. 

3. Ando T, Okada S, Niijima Y, Hashimoto K, Shimizu H, Tsuchiya T, Yamada M, Ohshima K, Mori M, Ono K. Impaired glucose tolerance, but not impaired fasting glucose, is a risk factor for early-stage atherosclerosis. Diabet Med. 27:1430-1435, 2010.

4. Daniel JA, Santos MA, Wang Z, Zang C, Schwab KR, Jankovic M, Filsuf D, Chen HT, Gazumyan A, Yamane A, Cho YW, Sun HW, Ge K, Peng W, Nussenzweig MC, Casellas R, Dressler GR, Zhao K, Nussenzweig A.PTIP promotes chromatin changes critical for immunoglobulin class switch recombination. Science. 329:917-923, 2010. 

5. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116: 5119-5125, 2010.

6. Hamatani H, Hiromura K, Kobatake K, Yoshida H, Kobayashi S, Yoneda N, Kayakabe K, Matsumoto T, Kuroiwa T, Ueki K, Nojima Y. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol. Clin Exp Nephrol.14:619-624, 2010. 

7. Handa H, Matsushima T, Nishimoto N, Inoue M, Saitoh T, Yokohama A, Tsukamoto N, Mitsui T, Nakahashi H, Toyama K, Karasawa M, Ogawara H, Nojima Y, Murakami H. Flow cytometric detection of human telomerase reverse transcriptase (hTERT) expression in a subpopulation of bone marrow cells. Leuk Res 34: 77-83, 2010. 

8. Horiguchi K, Hashimoto K, Hashizume M, Masuo T, Suto M, Okajo J, Handa H, Kaneko Y, Yokoo H, Sasaki A, Okada S, Yamada M, Tsukamoto N, Nojima Y, Nakazato Y, Mori M. Primary bilateral adrenal diffuse large B-cell lymphoma demonstrating adrenal failure. Intern Med.49:2241-2246, 2010. 

9. Hoshino T, Tahara K, Miyawaki K, Hatsumi N, Takada S, Miyawaki S, Sakura T. et al. Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib. Rinsho Ketsueki. 51:181-188, 2010. 

10. Hoshino T, Sakura T, Miyawaki K, Hatsumi N, Takada S, Maruya E, Saji H, Miyawaki S. Successful engraftment of a second transplant from unrelated cord blood identifying acceptable HLA Ag mismatches as treatment for primary graft failure possibly mediated by anti-HLA Abs after 'mega-dose' haploidentical PBSC transplantation. Bone Marrow Transplant. 45:1665-1667, 2010. 

11. Iida S, Chou T, Okamoto S, Nagai H, Hatake K, Murakami H, Takagi T, Shimizu K, Lau H, Takeshita K, Takatoku M, Hotta T. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol, 92, 127-128, 2010.

12. Ishida H, Matsuzaki-Moriya C, Imai T, Yanagisawa K, Nojima Y, Suzue K, Hirai M, Iwakura Y, Yoshimura A, Hamano S, Shimokawa C, Hisaeda H. Development of experimental cerebral malaria is independent of IL-23 and IL-17. Biochem Biophys Res Commun. 402:790-795, 2010. 

13. Ji Y, Resch W, Corbett E, Yamane A, Casellas R, Schatz DG. The in vivo pattern of binding of RAG1 and RAG2 to antigen receptor loci. Cell. 141:419-431, 2010.

14. Kanazawa Y, Saito Y, Supriatna Y, Tezuka H, Kotani T, Murata Y, Okazawa H, Ohnishi H, Kinouchi Y, Nojima Y, Ohteki T, Shimosegawa T, Matozaki T. Role of SIRPα in regulation of mucosal immunity in the intestine. Genes Cells 15, 1189-1200, 2010.

15. Klinman DM, Klaschik S, Tomaru K, Shirota H, Tross D, Ikeuchi H.Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants. Vaccine. 28:1919-23, 2010.

16. Kojima M, Nakamura N, Murayama K, Igarashi T, Matsumoto M, Matsuda H, Masawa N, Miura I, Morita Y. Reactive lymphoid hyperplasia with giant follicles associated with a posttherapeutic state of hematological malignancies. A report of eight cases. Tumori 96: 143-148, 2010.

17. Kotani T, Murata Y, Ohnishi H, Mori M, Kusakari S, Saito Y, Okazawa H, Bixby J.L, Matozaki T, Expression of PTPRO in the interneurons of adult mouse olfactory bulb. J Comp Neurol 518, 119-136, 2010.

18. Kuchen S, Resch W, Yamane A, Kuo N, Li Z, Chakraborty T, Wei L, Laurence A, Yasuda T, Peng S, Hu-Li J, Lu K, Dubois W, Kitamura Y, Charles N, Sun HW, Muljo S, Schwartzberg PL, Paul WE, O'Shea J, Rajewsky K, Casellas R.Regulation of microRNA expression and abundance during lymphopoiesis. Immunity. 32:828-39, 2010. 

19. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 95: 1857-1864, 2010. 

20. Maeshima A Daughter Cells: Properties, Characteristics and Stem Cells. Chapter V. Regeueration of the kidney: Involvement of Intra-and Extra-Renal Stem cells. Novapublishers p197-220, 2010.

21. Matsumoto T, Hess S, Kajiyama H, Sakairi T, Saleem MA, Mathieson PW, Nojima Y, Kopp JB. Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product. Am J Physiol Renal Physiol. 299:776-784, 2010.

22. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, Nojima Y, Sakai R. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res.70:5136-5146, 2010. 

23. Mori, M., Murata, Y., Kotani, T., Kusakari, S., Ohnishi, H., Saito, Y., Okazawa, H., Ishizuka, T., Mori, M., and Matozaki, T. Promotion of cell spreading and migration by vascular endothelial-protein tyrosine phosphatase (VE-PTP) in cooperation with integrins. J Cell Physiol 224, 195–204, 2010.

24. Morimoto, N., Murata, Y., Motegi, S.-I., Suzue, K., Saito, Y., Okazawa, H., Ohnishi, H., Kotani, T., Kusakari, S., Ishikawa, O.Requirement of SIRPα for protective immunity against Leishmania major. Biochem Biophys Res Commun 401, 385–389, 2010.

25. Murata, Y., Mori, M., Kotani, T., Supriatna, Y., Okazawa, H., Kusakari, S., Saito, Y., Ohnishi, H., and Matozaki, T.Tyrosine phosphorylation of R3 subtype receptor-type protein tyrosine phosphatases and their complex formations with Grb2 or Fyn. Genes Cells 15,513–524, 2010.

26. Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R. Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. Int J Hematol. 91:276-283, 2010.

27. Pavri R, Gazumyan A, Jankovic M, Di Virgilio M, Klein I, Ansarah-Sobrinho C, Resch W, Yamane A, Reina San-Martin B, Barreto V, Nieland TJ, Root DE, Casellas R, Nussenzweig MC.Activation-induced cytidine deaminase targets DNA at sites of RNA polymerase II stalling by interaction with Spt5. Cell. 143:122-33, 2010.

28. Saito Y, Iwamura H, Kaneko T, Ohnishi H, Murata Y, Okazawa H, Kanazawa Y, Sato-Hashimoto M, Kobayashi H, Oldenborg PA, Naito M, Kaneko Y, Nojima Y, Matozaki T. Regulation by SIRPα of dendritic cell homeostasis in lymphoid tissues. Blood.116:3517-3525, 2010. 

29. Sakairi T, Abe Y, Jat PS, Kopp JB. Cell-cell contact regulates gene expression in CDK4-transformed mouse podocytes. Am J Physiol Renal Physiol. 299:802-809, 2010.

30. Sakairi T, Abe Y, Kajiyama H, Bartlett LD, Howard LV, Jat PS, Kopp JB. Conditionally immortalized human podocyte cell lines established from urine. Am J Physiol Renal Physiol. 298:557-567,2010.

31. Sakamaki H, Miyawaki S, Ohtake S, et al. Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. Int J Hematol. 91:284-292, 2010.

32. Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, Niitsu N, Miwa H, Asaoku H, Kosugi H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamamoto K, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T; IVL Study Group in Japan. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci 101: 1480-1486, 2010. 

33. Suzuki R, Ohtake S, Takeuchi J, Nagai M, Kodera Y, Hamaguchi M, Miyawaki S. et al. The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. Int J Hematol. 91:303-309, 2010. 

34. Takeuchi S, Hiromura K, Tomioka M, Takahashi S, Sakairi T, Maeshima A, Kaneko Y, Kuroiwa T, Nojima Y. The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis. Nephron Exp Nephrol. 116:3-10, 2010.

35. Takizawa M, JS Kim, L Tessarollo, N McNeil, TJ Waldschmidt, R Casellas, T Ried, S Janz. Genetic reporter system for oncogenic Igh–Myc translocations in mice. Oncogene. 29:4113-4120, 2010

36. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, Shima H, Johnson RS, Hirao A, Suematsu M, Suda T. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 7:391-402, 2010.

37. Tomioka M, Hiromura K, Sakairi T, Takeuchi S, Maeshima A, Kaneko Y, Kuroiwa T, Takeuchi T, Nojima Y. Nestin is a novel marker for renal tubulointerstitial injury in immunoglobulin A nephropathy. Nephrology (Carlton). 15:568-574,2010. 

38. Tsuchida A, Paudyal B, Paudyal P, Matsumoto K, Ueki K, Naruse T, Kuroiwa T, Nojima Y, Komai M, A case report of acute renal failure associated with bee pollen contained in nutritional supplements. Therapeutic Apheresis and Dialysis 14, 93-97, 2010.

39. Tsuchida A, Paudyal B, Paudyal P, Ishii Y, Hiromura K, Nojima Y, Komai M, Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate. Experimental and Therapeutic Medicine 1: 777-781, 2010.

40. Yamamoto K, Okada Y, Nakamura K, Hiromura K, Nojima Y, Nakamura T. Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. Expert Opin Drug Saf. 9:447-457, 2010.

1. 石山謙, 宮脇修一 【正常核型急性骨髄性白血病】 正常核型急性骨髄性白血病の治療戦略 化学療法(解説/特集) 血液フロンティア20巻10号 P.1869-1875,2010.

2. 菊池拓, 宮脇修一【白血病診療essentials 日常臨床に必要な最新の診断と治療】 白血病治療の最前線 急性骨髄性白血病(解説/特集) 内科 106巻2号 P. 233-240, 2010.

3. 菊池拓, 宮脇修一【AML診療の新たな展開】 AMLにおける適切な寛解後療法(解説/特集) 血液・腫瘍科(0915-8529)60巻4号 P.415-42,2010.

4. 斉藤貴之、塚本憲史、村上博和 血液疾患における分子標的治療 ドラッグラグ解消に向けて Ⅲ.多発性骨髄腫 8.ベンダムスチンによる骨髄腫の治療医薬ジャーナル, 血液フロンティア医薬ジャーナル 第20巻第S-1号 P.245-253, 2010.

5. 島崎 千尋, 村上 博和, 澤村 守夫, 松田 正之, 木下 朝博, 畑 裕之, 杉浦 勇, 津下 圭太郎, 名倉 英一, 小杉 浩史, 伊藤 淳治, 清水 一之. 単クローン性γグロブリン血症における血清遊離軽鎖測定の臨床的有用性.臨床血液 51, P.245-252, 2010.

6. 直江知樹, 宮脇修一, 大西一功【臨床試験グループの現状と問題点】 Japan Adult Leukemia Study Group(JALSG) 過去・現在・未来(解説/特集) 腫瘍内科(1881-6568)6巻4号 P.290-296, 2010.

7. 永田安伸, 宮脇修一 高齢者の急性骨髄性白血病に対する治療選択と予後について(解説)血液・腫瘍科(0915-8529)60巻2号 P.206-212, 2010.

8. 半田寛、村上博和 造血貴腫瘍治療 2版 これは困ったぞ、どうしよう! 原発性マクログロブリン血症患者の意識が朦朧としてきた。血清IgMが11g/dlある。さて、どうしよう? 監修 押味和夫、編集 木崎昌弘、松村到。中外医学社, 2010.

9. 半田寛、村上博和。血液悪性疾患治療の現状 多発性骨髄腫。Medicina 47(13), 2159-2161, 2010.

10. 星野匠臣(済生会前橋病院 白血病治療センター), 田原研一, 宮脇恒太, 初見菜穂子, 高田覚, 宮脇修一, 佐倉徹 当施設においてdasatinibを投与した7症例の臨床的検討 臨床血液(0485-1439)51巻3号 P.181-188, 2010.


11. 宮脇修一(東京都立大塚病院 輸血科), 大竹茂樹, 清井仁, 坂巻壽, 宮崎泰司 白血病治療における若手血液内科医の育成 血液内科医の魂(第5回)(座談会) Pharma Medica(0289-5803)28巻12号 P.167-172, 2010.

12. 宮脇修一, 秋山暢, 神田善伸, 木村文彦, 柵木信男 白血病治療における若手血液内科医の育成 血液内科医の魂(第4回)(座談会) Pharma Medica(0289-5803)28巻11号 P.113-118, 2010.

13. 宮脇修一 血液疾患における分子標的治療 ドラッグラグ解消に向けて 白血病 クロファラビンの臨床効果(解説/特集) 血液フロンティア(1344-6940)20巻S-1 P.1499-1503, 2010.

14. 宮脇修一, 大西一功, 木村晋也, 芹生卓, 宮崎泰司 白血病治療における若手血液内科医の育成 血液内科医の魂(第3回)(座談会) Pharma Medica(0289-5803)28巻8号 P.185-190, 2010.

15. 宮脇修一,志関雅幸, 中世古知昭, 八田善弘, 半下石明 白血病治療における若手血液内科医の育成 血液内科医の魂(第2回)(座談会) Pharma Medica(0289-5803)28巻7号 P.125-130, 2010.

16. 宮脇修一, 猪口孝一, 黒川峰夫, 竹内仁, 泉二登志子 白血病治療における若手血液内科医の育成 血液内科医の魂(第1回)(座談会) Pharma Medica(0289-5803)28巻6号 P.99-104, 2010.

17. 宮脇修一【白血病治療の進歩】 急性骨髄性白血病の層別化治療(解説/特集) BIO Clinica(0919-8237)25巻7号 P.580-586, 2010.

18. 村上博和、鈴木憲史、澤村守夫. 多発性骨髄腫インフォームドコンセントCD-ROM Ver. 2. 中外製薬、Oct、2010.

19. 村上博和、半田寛 造血器腫瘍治療 2版 これは困ったぞ、どうしよう! 原発性アミロイドーシスの治療をどうしよう? 監修 押味和夫、編集 木崎昌弘、松村到 中外医学社,2010.

20. 村上博和 看護学大事典第2版、医学書院, 2010.

21. 村上博和 造血器腫瘍取扱い規約 第4部多発性骨髄腫 1.疾患概念・診断規準 日本血液学会 日本りんぱ網内系学会編、金原出版,2010.

22. 村上博和、半田寛、斉藤貴之 IMiDsの基礎と臨床 第Ⅱ章 臨床の実際 1.多発性骨髄腫とiMiDs 2)再発・難治例におけるiMiDs 医薬ジャーナル,2010

23. 村上博和. レブメイトを実行する医師の立場から.がんばりまっしょい11, 18-20, 2010.

24. 村上博和、半田寛、斉藤貴之、小河原はつ江. 特集 多発性骨髄腫. 多様な病期分類. カレントテラピー 28(3), 232-236, 2010.

25. 村上博和、半田寛、斉藤貴之. 多発性骨髄腫の最近の治療.綜合臨床59(8), 1835-1837, 2010.

26. 山上徹也、小笠原映子、徳田継祐、佐藤由美、横山知行、椎原康史、村上博和。「地域・大学循環型保健学リーダーの育成プログラム」の利用に関する意向調査-群馬県および近県の保健医療従事者を対象として-. Kitakanto Med J 60, 311-319, 2010.

27. 山田正仁(研究協力者 澤村守夫).アミロイドーシス診療 ガイドライン2010. 厚生労働科学研究費補助金 難治性疾患克服研究事業 アミロイドーシスに関する研究班

Comments